Funding Agency:
Alzheimer’s Drug Discovery Foundation

Frontotemporal dementia (FTD) encompasses a spectrum of neurodegenerative diseases with varied biological mechanisms, clinical symptoms and prognoses that come with unique challenges for clinical drug development. There are currently no approved treatments that delay or halt the progression of FTD disorders or that effectively treat symptoms. While there are increasing numbers of promising treatments entering clinical trials, the number remains small, and none have resulted in viable treatments.

The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) launched the Treat FTD Fund to provide critical funding for early-stage clinical trials that:

  • help address these challenges
  • build on emerging scientific understanding of biological mechanisms underlying FTD
  • stimulate the field to develop new therapies for FTD disorders
  • advance the development, validation and adoption of informative biomarkers
  • enable novel trial designs and technologies

Deadlines for Letters of Intent: Jan. 27, 2023

Agency Website

Eligibility Requirements

Funding is open to researchers and clinicians worldwide at:

  • Academic medical centers, universities or non-profits. Industry partnerships are encouraged.
  • Biotechnology companies. Existing companies and new startups are both eligible.
  • NOTE: All funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).



Amount Description

Up to $2,000,000 based on stage and scope of the trial. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and patient enrollment.

Funding Type



Medical Fellow/Resident
Post Doctoral Fellows


Engineering and Physical Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

January 27, 2023